Role of Glycosuria in SGLT2 Inhibitor–Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial
Diabetes · 01.02.2024 · 73 (2) · 250-259
DOI: 10.2337/db23-0448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 08.11.2023. Verfasst von Ele Ferrannini und 6 weiteren Autor:innen. Beteiligte Einrichtung: CNR Institute of Clinical Physiology, Pisa, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The CREDENCE study and this substudy were funded by Janssen Research & Development, LLC..
Abstract (Originalsprache)
SGLT2 inhibitors have been shown to provide pronounced reductions in cardiorenal outcomes, including cardiovascular death, heart failure, and renal failure. The mechanisms underlying these benefits remain uncertain. We hypothesized that the effects could be attributed to the elevated glycosuria induced by these drugs. Urine concentrations of glucose, creatinine, and ketones were measured at baseline and after 1 year of treatment with either placebo or canagliflozin 100 mg/day, in approximately 2,600 individuals from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial (enrolling patients with type 2 diabetes, chronic kidney disease (CKD), and albuminuria). Associations between glycosuria and the primary composite end point from CREDENCE, and secondary outcomes were assessed using Cox proportional hazards models. Canagliflozin treatment increased fractional urinary glucose excretion (± SD) from 3 ± 9% at baseline to 30 ± 26% at year 1 (vs. 5 ± 19% with placebo; P < 0.001). Patients in the canagliflozin arm and in the top quartile of urine glucose to creatinine ratio at year 1 were significantly protected for the primary end point (hazard ratio [HR] 0.42; 95% CI 0.30–0.61); similar results were seen for cases of hospitalized heart failure (HR 0.45; 95% CI 0.27–0.73) and all-cause death (HR 0.56; 95% CI 0.39–0.80). These associations persisted when adjustments were made for multiple conventional risk factors. Among patients with type 2 diabetes and CKD treated with canagliflozin, individuals with the highest glycosuria levels had the strongest protection against multiple cardiorenal outcomes. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CNR Institute of Clinical Physiology, Pisa, Italy.
- Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Janssen Research & Development, LLC, Spring House, PA.
ORCID-Profile: Ele Ferrannini, Anna Solini
Förderung
- The CREDENCE study and this substudy were funded by Janssen Research & Development, LLC.
Zitieren
APA
Ferrannini, E., Solini, A., Baldi, S., Scozzaro, T., Polidori, D., Natali, A., & Hansen, M. K. (2024). Role of Glycosuria in SGLT2 Inhibitor–Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial. Diabetes, 73(2), 250-259. https://doi.org/10.2337/db23-0448
Vancouver
Ferrannini E, Solini A, Baldi S, Scozzaro T, Polidori D, Natali A, et al. Role of Glycosuria in SGLT2 Inhibitor–Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial. Diabetes. 2024;73(2):250-259. doi:10.2337/db23-0448
BibTeX
@article{Ferrannini2024,
author = {Ferrannini, Ele and Solini, Anna and Baldi, Simona and Scozzaro, Tiziana and Polidori, David and Natali, Andrea and Hansen, Michael K},
title = {Role of Glycosuria in SGLT2 Inhibitor–Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial},
journal = {Diabetes},
year = {2024},
volume = {73},
number = {2},
pages = {250--259},
doi = {10.2337/db23-0448}
}
EUVIMED